Delaware Court Denies CareDx's Motion For Summary Judgment On Two Natera Patents; Achieves Key Objective For Trial Set To Begin On Jan. 22nd
Portfolio Pulse from Benzinga Newsdesk
The United States District Court for the District of Delaware denied CareDx's motion for summary judgment on two Natera patents, allowing the case to proceed to trial on January 22, 2024. Natera, Inc. (NASDAQ:NTRA) views this as a key objective achieved in protecting its cell-free DNA testing innovations from infringement by CareDx. In a related case, Natera had previously invalidated all three of CareDx's patents asserted against them.
December 11, 2023 | 5:53 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Natera, Inc. is set to proceed to trial after the court denied CareDx's motion for summary judgment on two patents. This development could be seen positively as Natera defends its intellectual property.
The court's decision to deny CareDx's motion for summary judgment is a legal victory for Natera, which may boost investor confidence in the company's ability to protect its intellectual property. This could have a positive short-term impact on NTRA's stock price as the market often reacts favorably to successful legal defenses of a company's core technologies.
CONFIDENCE 75
IMPORTANCE 70
RELEVANCE 80
NEGATIVE IMPACT
CareDx faces a setback as the court denies its motion for summary judgment against Natera, indicating a challenging legal battle ahead regarding patent infringement.
The denial of CareDx's motion for summary judgment suggests that the company may have a more difficult time defending its position in the upcoming trial. This could be perceived negatively by investors, potentially leading to a short-term decline in CDNA's stock price as the market often reacts unfavorably to increased legal uncertainty and potential threats to a company's competitive position.
CONFIDENCE 75
IMPORTANCE 70
RELEVANCE 80